08:08 AM EDT, 03/17/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Monday its drug Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell lung cancer.

The indication for the drug, also called durvalumab, is for patients whose disease has not progressed following platinum-based chemoradiation therapy, the company said.

The European Commission approval follows a positive opinion of the Committee for Medicinal Products for Human Use and is based on results from a phase 3 trial in which Imfinzi reduced the risk of death by 27%, the company said.